OASYS NOW: Pioneering the Future of Clinical Trials with AI
December 17, 2024, 5:13 am
In the bustling world of healthcare innovation, OASYS NOW stands out like a lighthouse in a storm. Fresh from its triumph at the Slush 100 competition, this Delft-based startup is not just basking in glory. It’s diving headfirst into action. With a €1 million equity investment from General Catalyst and Cherry Ventures, OASYS NOW is ready to reshape the landscape of clinical trials.
The company has forged a partnership with Progress Clinical Research. This collaboration aims to tackle one of the biggest hurdles in clinical research: patient recruitment. Think of it as a bridge connecting patients to life-saving treatments. OASYS NOW’s AI technology, ELaiGIBLE, is the engine driving this bridge. It automates the identification of eligible patients from electronic health records, transforming a cumbersome process into a streamlined operation.
Imagine a world where clinical trials are as easy as ordering a pizza. That’s the vision OASYS NOW is working towards. The traditional methods of patient recruitment are slow and inefficient, often leading to delays in bringing new treatments to market. ELaiGIBLE changes the game. It extracts and categorizes eligibility criteria from trial protocols, generating a prioritized list of candidates. This innovation reduces the time and cost associated with recruitment, addressing a critical bottleneck in clinical research.
The partnership with Progress Clinical Research is a significant leap forward. Progress, established in 2009, operates trial sites across the Netherlands. Their focus is on central nervous system, cardiometabolic, and immune diseases. By integrating ELaiGIBLE into their operations, they aim to reduce screen failures and improve the success rates of clinical trials. It’s a win-win situation, where patients gain access to cutting-edge treatments faster, and researchers can conduct trials more efficiently.
The implications of this partnership are profound. It’s not just about numbers; it’s about lives. Every day, patients wait for breakthroughs in treatment. OASYS NOW and Progress Clinical Research are committed to reducing that wait. They envision a future where personalized medicine is not just a dream but a reality for everyone. This collaboration is a step towards that future.
OASYS NOW’s journey is fueled by a passion for healthcare and technology. The startup’s CEO, Nima Salami, emphasizes the importance of this partnership. It’s about more than just technology; it’s about making a difference in people’s lives. The collaboration is a testament to the power of innovation in healthcare. It shows how technology can bridge gaps and create opportunities.
As the healthcare landscape evolves, the need for efficient solutions becomes more pressing. OASYS NOW is at the forefront of this evolution. Their AI-powered platform is not just a tool; it’s a catalyst for change. By automating patient recruitment, they are paving the way for more targeted and effective treatments. This is the essence of progress in medicine.
The startup ecosystem is buzzing with excitement. Investors are taking notice. With a solid backing from reputable firms, OASYS NOW is poised for growth. The healthcare sector is ripe for disruption, and OASYS NOW is leading the charge. Their innovative approach is attracting attention and investment, setting the stage for future advancements.
But the road ahead is not without challenges. The integration of AI in healthcare raises questions about ethics and data privacy. OASYS NOW must navigate these waters carefully. Trust is paramount in healthcare. Patients need to feel secure that their data is handled responsibly. OASYS NOW is committed to transparency and ethical practices, ensuring that patient welfare remains at the forefront of their operations.
The partnership with Progress Clinical Research is just the beginning. OASYS NOW has ambitious plans for the future. They aim to expand their technology beyond the Netherlands, reaching patients across Europe. The vision is clear: to become a leader in the field of clinical trial automation. With their innovative spirit and commitment to excellence, OASYS NOW is well on its way to achieving this goal.
In conclusion, OASYS NOW is not just another startup; it’s a beacon of hope in the healthcare industry. Their partnership with Progress Clinical Research is a significant step towards revolutionizing clinical trials. By harnessing the power of AI, they are breaking down barriers and accelerating the path to life-saving treatments. The future of personalized medicine is bright, and OASYS NOW is leading the way. In a world where time is of the essence, they are ensuring that patients receive the care they need, when they need it. The journey has just begun, and the possibilities are endless.
The company has forged a partnership with Progress Clinical Research. This collaboration aims to tackle one of the biggest hurdles in clinical research: patient recruitment. Think of it as a bridge connecting patients to life-saving treatments. OASYS NOW’s AI technology, ELaiGIBLE, is the engine driving this bridge. It automates the identification of eligible patients from electronic health records, transforming a cumbersome process into a streamlined operation.
Imagine a world where clinical trials are as easy as ordering a pizza. That’s the vision OASYS NOW is working towards. The traditional methods of patient recruitment are slow and inefficient, often leading to delays in bringing new treatments to market. ELaiGIBLE changes the game. It extracts and categorizes eligibility criteria from trial protocols, generating a prioritized list of candidates. This innovation reduces the time and cost associated with recruitment, addressing a critical bottleneck in clinical research.
The partnership with Progress Clinical Research is a significant leap forward. Progress, established in 2009, operates trial sites across the Netherlands. Their focus is on central nervous system, cardiometabolic, and immune diseases. By integrating ELaiGIBLE into their operations, they aim to reduce screen failures and improve the success rates of clinical trials. It’s a win-win situation, where patients gain access to cutting-edge treatments faster, and researchers can conduct trials more efficiently.
The implications of this partnership are profound. It’s not just about numbers; it’s about lives. Every day, patients wait for breakthroughs in treatment. OASYS NOW and Progress Clinical Research are committed to reducing that wait. They envision a future where personalized medicine is not just a dream but a reality for everyone. This collaboration is a step towards that future.
OASYS NOW’s journey is fueled by a passion for healthcare and technology. The startup’s CEO, Nima Salami, emphasizes the importance of this partnership. It’s about more than just technology; it’s about making a difference in people’s lives. The collaboration is a testament to the power of innovation in healthcare. It shows how technology can bridge gaps and create opportunities.
As the healthcare landscape evolves, the need for efficient solutions becomes more pressing. OASYS NOW is at the forefront of this evolution. Their AI-powered platform is not just a tool; it’s a catalyst for change. By automating patient recruitment, they are paving the way for more targeted and effective treatments. This is the essence of progress in medicine.
The startup ecosystem is buzzing with excitement. Investors are taking notice. With a solid backing from reputable firms, OASYS NOW is poised for growth. The healthcare sector is ripe for disruption, and OASYS NOW is leading the charge. Their innovative approach is attracting attention and investment, setting the stage for future advancements.
But the road ahead is not without challenges. The integration of AI in healthcare raises questions about ethics and data privacy. OASYS NOW must navigate these waters carefully. Trust is paramount in healthcare. Patients need to feel secure that their data is handled responsibly. OASYS NOW is committed to transparency and ethical practices, ensuring that patient welfare remains at the forefront of their operations.
The partnership with Progress Clinical Research is just the beginning. OASYS NOW has ambitious plans for the future. They aim to expand their technology beyond the Netherlands, reaching patients across Europe. The vision is clear: to become a leader in the field of clinical trial automation. With their innovative spirit and commitment to excellence, OASYS NOW is well on its way to achieving this goal.
In conclusion, OASYS NOW is not just another startup; it’s a beacon of hope in the healthcare industry. Their partnership with Progress Clinical Research is a significant step towards revolutionizing clinical trials. By harnessing the power of AI, they are breaking down barriers and accelerating the path to life-saving treatments. The future of personalized medicine is bright, and OASYS NOW is leading the way. In a world where time is of the essence, they are ensuring that patients receive the care they need, when they need it. The journey has just begun, and the possibilities are endless.